Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab

Cesare Hassan, E Ierardi, O Burattini, V De Francesco, A Zullo, G Stoppino, C Panella, S. Morini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

32 Citazioni (Scopus)

Abstract

Treatment with the anti-tumour necrosis factor alpha monoclonal antibody infliximab has been shown to be effective in moderate-to-severe ulcerative colitis. However, its effect on the mucosal histopathological abnormalities of this disease is largely unknown. This study aimed to assess the immunohistological effect of infliximab in ulcerative colitis.
Lingua originaleEnglish
pagine (da-a)811-817
Numero di pagine7
RivistaDIGESTIVE AND LIVER DISEASE
Volume39
DOI
Stato di pubblicazionePubblicato - 2007
Pubblicato esternamenteYes

Keywords

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Colitis, Ulcerative
  • Down-Regulation
  • Female
  • Humans
  • Immunologic Factors
  • Inflammation
  • Male
  • Middle Aged
  • Tumor Necrosis Factor-alpha

Fingerprint

Entra nei temi di ricerca di 'Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab'. Insieme formano una fingerprint unica.

Cita questo